Probiotics Expressing GLP-1 as an Aid to prevent or Treat Diabetes
- 詳細技術說明
- The technology provides recombinant cells and methodsusing commensal bacteria for the prevention and treatment of diabetes ormetabolic syndromes.
- *Abstract
-
The humangastrointestinal (GI) tract is home to hundreds of bacterial species requiredfor normal metabolism. Commensal bacteria in the GI tract coexist with theirhuman hosts and with each other through a complex system of checks and balances.
The FDA considerscommensal bacteria safe, having already approved them as food supplements.Commensal bacteria have great potential as a drug delivery vehicle, both aspreventive means for bacterial diseases and as replacement therapy fordiseases.
A team at Cornellhas engineered commensal bacteria that express the protein of interest GLP-1when triggered by glucose. GLP-1activates insulin synthesis in pancreatic β cells by binding to the membranereceptor GLP-1R.
Here, the teamrelies on the fact that intestinal epithelial cells convert intoinsulin-secreting cells when induced by GLP-1. This finding paves the way for new therapeutic approach to insulindependent diabetes through the gut.
Potential Applications
Probioticsas aid in the treatment of diabetes.
Advantages
- Compatibility of commensal strains with the human host
- Simple oral dosing
- No significant background expression
- Persistence of the strain in the gut
- May even eliminate the need for insulin injection
- Allows for delivery of GLP-1 to intestinal membrane.
- *Licensing
- Jeff Fearnjcf55@cornell.edu607-254-4502
- 其他
-
- Patents issued in the U.S. 8,771,668 (D-4291) and 9,265,842 (D-5208)
- Patents issued in the Europe EP2274416 (D-4291) and EP2627770(D-5208)
- Duan, F., Curtis, K. L. and March, J. C. (2008).Secreting insulinotropic proteins from commensal bacteria: rewiring the gut totreat diabetes. Applied and Environmental Microbiology, 74: 7437-7438
- Duan,F., Liu, J. H. and March, J. C. (2015). Engineered commensal bacteria reprogram intestinal cells intoglucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes, 64: 1794-1803.
- 國家/地區
- 美國
